Highlights Curative Biotechnology, Inc.

Equities

CUBT

US23128N1081

End-of-day quote OTC Markets Other stock markets 06:00:00 2024-05-19 pm EDT			5-day change	1st Jan Change
0.0181 ^USD	+41.96%		-25.51%	-15.02%

May. 06	Curative Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $7.999998 million.	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Curative Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	May. 06	CI
Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $7.999998 million.	Nov. 25	CI
Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $7.999998 million.	23-09-07	CI
Curative Biotechnology, Inc. Announces Establishment of Japanese Subsidiary for Licensing Transactions and Asset Acquisitions	23-06-07	CI
Curative Biotechnology, Inc. Announces Completion of IND Enabling Reformulated Metformin HCL Eye Drop Study	23-01-05	CI
Curative Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-16	CI
Curative Biotechnology, Inc. has filed an IPO in the amount of $7.999998 million.	22-11-07	CI
Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $8 million.	22-10-31	CI
Curative Biotechnology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-09-01	CI
Curative Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-06-29	CI
Curative Biotechnology, Inc. has filed an IPO.	22-04-15	CI
Curative Biotechnology Announces Cooperative Research and Development Agreement with the National Eye Institute	22-03-21	CI
Curative Biotechnology Announces Ocular Tolerance Evaluation of Metformin Eye Drop Formulations for Treatment of Macular Degeneration	21-11-24	CI
Curative Biotechnology Announces IMT504 License For Development Of Proprietary Next-Gen COVID-19 Vaccine	21-10-07	CI
Connectyx Announces Grant of Exclusive Worldwide License from National Institutes of Health for Repurposing Metformin to Treat Degenerative Eye Disease	21-02-04	CI
Connectyx Announces Grant of License from National Institutes of Health for Use of Novel Monoclonal Antibody to Treat Glioblastoma	20-10-16	CI
Connectyx Technologies Holdings Group, Inc. Announces Strategic Relationship with Mid-Atlantic Biotherapeutics, Inc. for Treatment of Symptomatic Rabies	20-08-27	CI
Connectyx in Licensing Discussions for Novel Monoclonal Antibody to Treat Pediatric Glioblastoma	20-07-06	CI
Connectyx Technologies Holdings Group, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-19	CI
Connectyx Launches MedFlash Canada	13-06-04	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Curative Biotechnology, Inc.

Equities

CUBT

US23128N1081

Highlights

Filters